RAN and chronic kidney disease: The addition of KN93 (CaMKII inhibitor) and RAN (late sodium current inhibitor) to CKD and sham cardiomyocytes produced a significant decrease in Ca2+ transients in the CKD group but little effect in the sham group (Figure 4A,4).